Gubra - Extraordinary general meeting

MFN Publicerad: 01 Nov 2023 10:40

Today, at 10:00 CET, Gubra A/S (“Gubra”) held an extraordinary general meeting at Plesner Advokatpartnerselskab, Amerika Plads 37, DK-2100 Copenhagen.

All proposals presented to the general meeting were adopted:

Item 1
Election of Monika Leesl and Astrid Haug as new members to the board of directors.

The board of directors hereafter consists of Jacob Jelsing (chair), Alexander Thomas Martensen-Larsen (deputy chair), Henriette Rosenquist, Arndt Justus Georg Schottelius, Monika Lessl and Astrid Haug.

Item 2
Authorization to file and register the adopted resolution with the Danish Business Authority.

About Gubra
Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen in 2023, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

Börskollen

För dig med koll på börsen

Pressmeddelande

Gubra - Extraordinary general meeting

Bifogade filer

Nyheter om Gubra

Läses av andra just nu

Om aktien Gubra

Senaste nytt